The news closely follows an announcement from Moderna, which also said that it would be testing an additional booster dose of its COVID-19 vaccine.
The aim of developing such booster doses is to determine if they could further increase the level of neutralising antibodies that fight against emerging strains.
“Every time a new variant comes up we should be able to test whether or not [our vaccine] is effective,” Pfizer chief executive officer Albert Bourla told Bloomberg.
“Once we discover something that it is not as effective, we will very, very quickly be able to produce a booster dose that will be a small variation to the current vaccine,” he added.
Last week, Pfizer/BioNTech published new results from a laboratory study of their COVID-19 vaccine, which found that the jab is likely to protect against the new coronavirus strain discovered in the UK…